Pelvic RT technique | |
---|---|
3D-CRT | 23 (92.0%) |
IMRT | 2 (8.0%) |
Pelvic RT dose (Gy, median) | 45 (range 44–50.4) |
Pelvic RT fractionations (median) | 25 (range 22–28) |
Pelvic RT BED (Gy, median, α/β = 3) | 72 (range 72–80.64) |
Pelvic RT BED (Gy, median, α/β = 10) | 53.1 (range 52.8–59.47) |
Lymph node boost | |
Sequential | 8 (32.0%) |
Simultaneous | 2 (8.0%) |
No | 15 (60.0%) |
Bladder (pelvic RT) | |
Mean dose (Gy, average ± SD) | 46.3 ± 3.8 |
Mean BED (Gy, average ± SD, α/β = 3) | 73.9 ± 7.3 |
Maximum dose (Gy, average ± SD) | 50.0 ± 3.4 |
Maximum BED (Gy, average ± SD, α/β = 3) | 82.2 ± 6.9 |
Rectum (pelvic RT) | |
Mean dose (Gy, average ± SD) | 44.2 ± 3.9 |
Mean BED (Gy, average ± SD, α/β = 3) | 69.4 ± 7.7 |
Maximum dose (Gy, average ± SD) | 49.4 ± 2.5 |
Maximum BED (Gy, average ± SD, α/β = 3) | 80.9 ± 4.6 |
SABR boost dose (Gy, median) | 25 (range 20–33) |
SABR boost fractions | |
4 | 4 (16.0%) |
5 | 17 (68.0%) |
6 | 4 (16.0%) |
SABR boost BED (Gy, median, α/β = 3) | 66.7 (range 53.3–93.5) |
SABR boost BED (Gy, median, α/β = 10) | 37.5 (range 30–51.2) |
Total volume of PTV (cc) | 120.0 (range 70.9–412.1) |
Bladder (SABR) | |
Mean dose (Gy, average ± SD) | 12.3 ± 4.4 |
Mean BED (Gy, average ± SD, α/β = 3) | 23.1 ± 11.6 |
Maximum dose (Gy, average ± SD) | 25.3 ± 3.1 |
Maximum BED (Gy, average ± SD, α/β = 3) | 68.4 ± 11.0 |
D2cc EQD2 (Gy, average ± SD, α/β = 3) | 31.4 ± 6.8 |
Cumulative D2cc EQD2 (Gy, average ± SD, α/β = 3 | 79.9 ± 6.1 |
Rectum (SABR) | |
Mean dose (Gy, average ± SD) | 11.4 ± 2.9 |
Mean BED (Gy, average ± SD, α/β = 3) | 20.6 ± 7.5 |
Maximum dose (Gy, average ± SD) | 24.5 ± 3.5 |
Maximum BED (Gy, average ± SD, α/β = 3) | 65.2 ± 12.7 |
D2cc EQD2 (Gy, average ± SD, α/β = 3) | 34.8 ± 6.9 |
Cumulative D2cc EQD2 (Gy, average ± SD, α/β = 3 | 76.5 ± 6.2 |